Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions.
about
Monitoring immune-checkpoint blockade: response evaluation and biomarker development.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients.The role of radiology in the evaluation of the immunotherapy efficacy.Pitfalls in the radiological response assessment of immunotherapy.Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.
P2860
Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Immune-Related Tumor Response ...... tcome and Treatment Decisions.
@en
Immune-Related Tumor Response ...... tcome and Treatment Decisions.
@nl
type
label
Immune-Related Tumor Response ...... tcome and Treatment Decisions.
@en
Immune-Related Tumor Response ...... tcome and Treatment Decisions.
@nl
prefLabel
Immune-Related Tumor Response ...... tcome and Treatment Decisions.
@en
Immune-Related Tumor Response ...... tcome and Treatment Decisions.
@nl
P2093
P2860
P1476
Immune-Related Tumor Response ...... tcome and Treatment Decisions.
@en
P2093
Anita Giobbie-Hurder
Elizabeth I Buchbinder
F Stephen Hodi
Michael P Manos
Mizuki Nishino
Nancy Bailey
Nikhil H Ramaiya
Patrick A Ott
P2860
P304
P356
10.1158/1078-0432.CCR-17-0114
P407
P577
2017-06-07T00:00:00Z